Patents by Inventor Stewart Craig

Stewart Craig has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Human mesenchymal stem cells
    Patent number: 6387367
    Abstract: Human mesenchymal stem cells having the phenotype SH3+, CD45+ can be isolated. These precursor mesenchymal item cells are useful for treatment of patients in need of mensenchymal stem cell.
    Type: Grant
    Filed: May 28, 1999
    Date of Patent: May 14, 2002
    Assignee: Osiris Therapeutics, Inc.
    Inventors: Janice M. Davis-Sproul, Mark Aaron Moorman, Renee Marie McNeil, Donald William Simonetti, Jr., Lora Catherine Hammill, Stewart Craig
  • Stem cell inhibiting proteins
    Patent number: 6057123
    Abstract: Proteinaceous molecules with stem cell inhibition activity are analogues of LD78 or MIP-1.alpha. which have mutations to prevent or reduce multimer formation beyond certain stages (for example a dodecamer). Aggregate formation is therefore inhibited, and the resulting low molecular weight monomers (or oligomers) have improved solution properties leading to enhanced productivity and greater therapeutic utility as stem cell protective agents, which are useful in tumour therapy.
    Type: Grant
    Filed: March 8, 1993
    Date of Patent: May 2, 2000
    Assignee: British Biotech Pharmaceuticals Limited
    Inventors: Stewart Craig, Michael George Hunter, Richard Mark Edwards, Lloyd George Czaplewski, Richard James Gilbert
  • Stem cell inhibiting proteins
    Patent number: 5856301
    Abstract: Proteinaceous molecules with stem cell inhibition activity are analogues of LD78 or MIP-1.alpha. which have mutations to prevent or reduce multimer formation beyond certain stages (for example a dodecamer). Aggregate formation is therefore inhibited, and the resulting low molecular weight monomers (or oligomers) have improved solution properties leading to enhanced productivity and greater therapeutic utility as stem cell protective agents, which are useful in tumour therapy.
    Type: Grant
    Filed: May 26, 1995
    Date of Patent: January 5, 1999
    Assignee: British Biotech Pharmaceuticals Limited
    Inventors: Stewart Craig, Michael George Hunter, Richard Mark Edwards, Lloyd George Czaplewski, Richard James Gilbert
  • PDGF-B analogues
    Patent number: 5512545
    Abstract: PDGF-B analogues are prepared in which an amino acid residue at a protease site is replaced with the corresponding amino acid residue from PDGF-A. The polypeptide is obtained at yields which are five to ten times greater than that for naturally occurring PDGF-B and retains the biological activity of the natural polypeptide.
    Type: Grant
    Filed: August 31, 1993
    Date of Patent: April 30, 1996
    Assignees: British Biotech Pharmaceuticals Limited, Pfizer Limited
    Inventors: David Brown, Richard M. Edwards, Stewart Craig, Anne L. Cook, John M. Clements
  • Human tissue plasminogen activator analogue having substitutions at amino acid positions 66, 67 and 68
    Patent number: 5232847
    Abstract: Tissue plasminogen activator (t-PA) analogues have at least one substitution in the growth factor (GF) domain that at least partially reduces hepatic receptor binding without substantially jeopardising physico-chemical stability in blood or fibrinolytic activity. This results in a longer plasma half life. Substitutions in the beta-sheet encompassing residues 63-72, especially at Leu 66 and/or Tyr 67 and/or Phe 68, are particularly preferred.
    Type: Grant
    Filed: December 11, 1990
    Date of Patent: August 3, 1993
    Assignee: British Bio-Technology Limited
    Inventors: Richard M. Edwards, Keith Dawson, Anthony Fallon, Stewart Craig